terminology and guidelines for glaucoma ii - Kwaliteitskoepel

More documents

Recommendations

Info

$Refractiechirurgie - Nederlands Oogheelkundig Gezelschap$

25) Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW, Guire KE, Mills RP, CIGTS Study Group. The Collaborative Initial Glaucoma Treatment Study (CIGTS): Interim Quality of Life Findings Following Initial Medical or Surgical Treatment of Glaucoma. Ophthalmology 2001;108:1954-65. 26) Bigger JF. A comparison of patient compliance in treated vs. untreated ocular hypertension. Trans Am Acad Ophthalmol Otolaryngol. 1976;81:277-285. 27) Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed A novel assessment technique. JAMA 1989 Jun 9;261(22):3273-3277. 28) Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26(3):233-236. 29) Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984;6:592-599. 30) Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000;22(2):167-208. 31) Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. Acta Ophthalmol Scand 2001;79(2):121-124. Comments: Acta Ophthalmol Scand. 2001;79(2):107. 32) Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta ophthalmol Scand 2001;79:116-120. 33) Baudouin C, Nordmann JP, Denis P, Creuzot-Garcher C, Allaire C, Trinquand C. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol 2002;240(11):929-935. 34) Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preser - vative free glaucoma medication. Br J Ophthalmol 2002; 86(4):418-423. 35) Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M, Bechetoille A. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999; 106(3):556-563. 36) Goldberg I. Should β blockers be abandoned as initial monotherapy in chronic open-angle glaucoma The controversy. Br J Ophthalmol 2002;86:691-695. 37) Anton A. Should β blockers be abandoned as initial monotherapy in chronic open-angle glaucoma View 1. Br J Ophthalmol 2002;86:692-693. 38) Skuta GL. Should β blockers be abandoned as initial monotherapy in chronic open-angle glaucoma View 2. Br J Ophthalmol 2002;86:693-694. 39) Stamper, RL. Primary drug treatment for glaucoma: Beta-blockers versus other medications for glaucoma. I. Individualize Initial Therapy. Surv Ophthalmol 2002;63-73. 40) Wigginton SA, Higginbotham EJ. Primary drug treatment for glaucoma: Beta-blockers versus other medications for glaucoma. II. Choosing beta-blockers for initial medical therapy for glaucoma. Surv Ophthalmol 2002;63-73. 41) Mittag TW. Adrenergic and dopaminergic drugs in glaucoma. In: Ritch R, Shields MB, Krupin T (eds). The Glaucomas. St. Louis, Mosby, 1989;1409-1424. 42) Gieser SC, Juzych M, Robin AL, Schwartz GF. Clinical pharmacology of adrenergic drugs. In: Ritch R, Shields MB, Krupin T (eds). The Glaucomas. St. Louis, Mosby, 1989;1425-1448. 43) Radius RL. Use of betaxolol in the reduction of elevated intraocular pressure. Arch Ophthalmol 1983;101:898. 44) Nardin GF, Zimmerman TJ. Ocular Cholinergic agents. In: Ritch R, Shields MB, Krupin T (eds). The Glaucomas. St. Louis, Mosby, 1996;66:1399-1409. 45) Drance SM, Nash PA. The dose response of human intraocular pressure to pilocarpine. Can J Ophthalmol 1971;6:9. 46) Lippa EA. Carbonic anhydrase inhibitors. In: Ritch R, Shields MB, Krupin T (eds). The Glaucomas. St. Louis, Mosby, 1996;70:1463-1482. 47) Camras CB. Prostaglandins. In: Ritch R, Shields MB, Krupin T (eds). The Glaucomas. St. Louis, Mosby, 1989;1449-1461. 48) Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavan Latanoprost Study Group. Ophthalmology 1996;103:126-137. Ch. 3 - 40 EGS
49) Waewar RE, Bullock JD, Ballal D. cystoid macular edema and anterior uveitis associated with latanoprost use. Ophthalmology 1998;105:263-368. 50) Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1- year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20-26. 51) Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003;110(3):609-614. 52) Hayreh SS, Podhajsky P and Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol 1999;128:301-309. 53) Higginbotham BJ, Schuman JS, Goldberg I, et al. Bimatropost Study Group 1 and 2. One-year randomized study comparing Bimatoprost and Timolol in Glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-1289. 54) Alm A, Camras CB and Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and he United States. Surv Ophthalmol 1997;41 Suppl 2:105-110. 55) Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-484. 56) Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twicedaily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45 Suppl 4:S361-368. 57) Brubaker RF, Schoff EO, Nau CB et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;11:19-24. 58) Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL and Whitcup SM for the Bimatoprost/Latanoprost Study Group. A Six-Months Randomized Clinical Trial Comparing the IOP- Lowering Efficacy of Bimatoprost and Latanoprost in Patients With Ocular Hypertension or Glaucoma. Am J Ophthalmol 2003. 59) K. Parrish R, Palmberg P, Sheu WP for the XLT Study Group. A Comparison of Latanoprost, Bimatoprost and Travoprost in Patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator, Multicenter Study. Am J Ophthalmol, 2003. 60) Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twicedaily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45 Suppl 4:S361-368. 61) Azuma I, Masuda K, Kitazawa Y, Yamamura H. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-525. 62) Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41(Suppl 2):S129-138. 63) Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997;6:430-432. 64) Brown SM. Increased iris pigment in a child due to latanoprost. Arch Ophthalmol 1998;116:1683-1684. 65) Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115:1206-1208. 66) Sudesh S, Cohen EJ, Rapuano CJ, Wilson RP. Corneal toxicity associated with latanoprost. Arch Ophthalmol 1999;117:539-540. 67) Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127:602-604. 68) Warwar RE, Bullock JD. Latanoprost-induced uveitis. Surv Ophthalmol 1999;43:466-468. 69) Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol 1999;117:34-40. 70) Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106:1024- 1029. 71) Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84:710-713. 72) Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1998;236(8):577-581. 73) Sponsel WE, Paris G, Trigo Y, Pena M. Comparative effects of latanoprost (Xalaton TM ) and unoprostone Ch. 3 - 41 EGS
Page 2 and 3:
ISBN: 88-87434-13-1 Editrice DOGMA
Page 4 and 5:
ACKNOWLEDGEMENT This work was made
Page 6 and 7:
2.2.5 - Primary Open-Angle Glaucoma
Page 8 and 9:
Foreword These Definitions and Guid
Page 10 and 11:
INTRODUCTION The aim of the book is
Page 12 and 13:
Since resources are limited worldwi
Page 14 and 15:
II - RANDOMIZED CONTROLLED TRIALS F
Page 16 and 17:
II.3 - COLLABORATIVE NORMAL TENSION
Page 18 and 19:
No stratification for stage of dise
Page 20 and 21:
II. 6. 3 - from CNTG 1. Therapy tha
Page 22 and 23:
References 1) The Ocular Hypertensi
Page 24 and 25:
I - QUESTIONS TO ASK TO YOUR GLAUCO
Page 26 and 27:
III - ABNORMAL THRESHOLD VISUAL FIE
Page 28 and 29:
V - GONIOSCOPIC OPEN ANGLES SOME DI
Page 30 and 31:
VII - TREATMENT STEPLADDER JUVENILE
Page 32 and 33:
IX - MONOTHERAPY (in alphabetic ord
Page 34 and 35:
XI - MANAGEMENT ACUTE ANGLE CLOSURE
Page 36 and 37:
XIII - ANTIMETABOLITES FOR WOUND MO
Page 38 and 39:
CHAPTER 1 PATIENT EXAMINATION
Page 40 and 41:
Other methods 22-25 : Air-puff tono
Page 42 and 43:
References 1) Martin XD. Normal int
Page 44 and 45:
1.2 - GONIOSCOPY Gonioscopy is a fu
Page 46 and 47:
1 2 3 4 Fig. 1 Dynamic indentation
Page 48 and 49:
The Spaeth classification Insertion
Page 50 and 51:
References 1) Palmberg P. Gonioscop
Page 52 and 53:
small - size mid - size large - siz
Page 54 and 55:
Fig. 5 A) Cirumlinear vessel, B) Ba
Page 56 and 57:
1.3.4.3 - OCT The Optical Coherence
Page 58 and 59:
31) Carpineto P, Ciancaglini M, Zup
Page 60 and 61:
central 24 or 30 central degrees re
Page 62 and 63:
A retinal sensitivity value worse t
Page 64 and 65:
HODAPP CLASSIFICATION 31 EARLY GLAU
Page 66 and 67:
References 1) Bengtsson B, Heijl A,
Page 68 and 69:
1.5 - BLOOD FLOW 1.5.1 - VASCULAR F
Page 70 and 71:
28) Flammer J, Orgul S, Costa VP, O
Page 72 and 73:
All forms of glaucoma should be cla
Page 74 and 75:
2.2 - PRIMARY OPEN-ANGLE GLAUCOMAS
Page 76 and 77:
2.2.4 - PRIMARY OPEN-ANGLE GLAUCOMA
Page 78 and 79: 2.3 - SECONDARY OPEN-ANGLE GLAUCOMA
Page 80 and 81: 2.3.1.6 - Glaucoma due to intraocul
Page 82 and 83: 2.4 - PRIMARY ANGLE-CLOSURE Primary
Page 84 and 85: Systemic Risk factors for primary a
Page 86 and 87: OCCLUDABLE ANGLE: “Occludable”
Page 88 and 89: 2.5.3 - SECONDARY ANGLE-CLOSURE GLA
Page 90 and 91: CHAPTER 3 TREATMENT PRINCIPLES and
Page 92 and 93: Furthermore, blindness may occur de
Page 94 and 95: T A R G E T I O P Target IOP range
Page 96 and 97: Practical points for topical medica
Page 98 and 99: 3.3.1.1 - Category: ADRENERGIC AGON
Page 100 and 101: 3.3.1.2 - Category: ADRENERGIC ANTA
Page 102 and 103: 3.3.1.3 - Category: CARBONIC ANHYDR
Page 104 and 105: 3.3.1.4 - Category: PARASYMPATHOMIM
Page 106 and 107: 3.3.1.5 - Category: PROSTAGLANDIN D
Page 108 and 109: Drug interactions Precipitation occ
Page 110 and 111: COMBINATION THERAPY Starting* Addit
Page 112 and 113: 3.3.2.2 - Category: ADRENERGIC ANTA
Page 114 and 115: Pregnancy and nursing mothers Only
Page 116 and 117: 3.5 - LASER SURGERY 3.5.1 - LASER I
Page 118 and 119: 3.5.2 - LASER TRABECULOPLASTY 77-89
Page 120 and 121: 3.5.4 - CYCLOPHOTOCOAGULATION Indic
Page 122 and 123: Although medical therapy is still t
Page 124 and 125: 3.6.4 - COMPLEX CASES Complicated g
Page 126 and 127: Post-operative use Concentration: 0
Page 130 and 131: (Rescula TM ) in patients with glau
Page 132 and 133: in white patients with open-angle g
Page 134 and 135: CHAPTER 4 TREATMENT GUIDELINES
Page 136 and 137: 4.2 - PRIMARY OPEN-ANGLE GLAUCOMAS
Page 138 and 139: 4.2.7 - OCULAR HYPERTENSION (OH) Al
Page 140 and 141: 4.3.1.7 - Glaucoma associated with
Page 142 and 143: • Withdrawal of aqueous from vitr
Page 144 and 145: 4.5 - SECONDARY ANGLE-CLOSURE GLAUC
Page 146 and 147: 4.5.3 - SECONDARY ANGLE-CLOSURE GLA
Page 148 and 149: NOTES
Page 150 and 151: NOTES
Page 152: NOTES
show all

terminology and guidelines for glaucoma ii - Kwaliteitskoepel

Create successful ePaper yourself

Delete template?

Save as template?